Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy
Transthyretin cardiac amyloidosis (ATTR-CA) has been traditionally considered a rare and inexorably fatal condition. ATTR-CA now is an increasingly recognised cause of heart failure and mortality worldwide with effective pharmacological treatments. Advances in non-invasive diagnosis, coupled with th...
| Prif Awduron: | , , |
|---|---|
| Fformat: | Erthygl |
| Iaith: | English |
| Cyhoeddwyd: |
Ubiquity Press
2023-11-01
|
| Cyfres: | Global Heart |
| Pynciau: | |
| Mynediad Ar-lein: | https://account.globalheartjournal.com/index.php/up-j-gh/article/view/1275 |